ReviewFrontiers in immunology2020
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Prognostic role of the pretreatment systemic immune-inflammation index in patients with glioma: A meta-analysis.Frontiers in neurology · 2023Pooled it
- Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis.Arquivos de neuro-psiquiatria · 2022Pooled it
- A Systematic Review of the Tumor-Infiltrating CD8Frontiers in immunology · 2021Pooled it
- Emerging frontiers in glioma therapy: the evolving role of glioma vaccines.Frontiers in immunology · 2026Review
- TREM1 unleashes immunosuppression in glioma: targeting macrophage polarization as a new therapeutic vulnerability.Frontiers in immunology · 2026Article
- Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025Review
- Characterization and prognostic of CD8 + TIM3 + CD101 + T cells in glioblastoma multiforme.Cell & bioscience · 2025Article
- Mediation Mendelian randomization analysis of immune cell phenotypes and glioma risk: unveiling the regulation of cerebrospinal fluid metabolites.Discover oncology · 2025Article
- Oligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies.Biomedicines · 2025Review
- Integrative Disulfidptosis-Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma.Journal of cellular and molecular medicine · 2025Article
- Relationship between CTF1 gene expression and prognosis and tumor immune microenvironment in glioma.European journal of medical research · 2025Article
- A Novel Signature of Disulfidptosis-Related lncRNAs Predicts Prognosis in Glioma: Evidence From Bioinformatic Analysis and Experiments.International journal of genomics · 2025Article
- Systematic Analysis of an Immune-Related Gene Signature for Predicting Prognosis and Immune Characteristics in Primary Lower Grade Glioma.BioMed research international · 2025Article
- Zinc finger protein 800 (ZNF800) promotes proliferation and migration of lower-grade glioma and is associated with immune infiltration.PloS one · 2025Article
- Novel signature of ferroptosis-related long non-coding RNA to predict lower-grade glioma overall survival.Discover oncology · 2024Article
- Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors.Oncology reports · 2024Article
- Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment.Experimental hematology & oncology · 2024Review
- A Four-Gene Panel for the Prediction of Prognosis and Immune Cell Enrichment in Gliomas.Molecular biotechnology · 2024Article
- Comprehensive analysis of the prognostic and immunological signature of TNFAIP8 family genes in human glioma.Scientific reports · 2024Article
- IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma.Pharmaceutics · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is the most malignant primary tumor of the central nervous system and is characterized by an extremely low overall survival. Recent breakthroughs in cancer therapy using immune checkpoint blockade have attracted significant attention. However, despite representing the most promising (immunotherapy) treatment for cancer, the clinical application of immune checkpoint blockade in glioma patients remains challenging due to the "cold phenotype" of glioma and multiple factors inducing resistance, both intrinsic and acquired. Therefore, comprehensive understanding of the tumor microenvironment and the unique immunological status of the brain will be critical for the application of glioma immunotherapy. More sensitive biomarkers to monitor the immune response, as well as combining multiple immunotherapy strategies, may accelerate clinical progress and enable development of effective and safe treatments for glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.